Expression of LC3B and FIP200/Atg17 in brain metastases of breast cancer

Nooshin Hashemi-Sadraei, Gaëlle M. Müller-Greven, Fadi W. Abdul-Karim, Ilya Ulasov, Erinn Downs-Kelly, Monica E. Burgett, Adam Lauko, Maha A. Qadan, Robert J. Weil, Manmeet S. Ahluwalia, Lingling Du, Richard A. Prayson, Samuel T. Chao, Thomas G. Budd, Jill Barnholtz-Sloan, Amy S. Nowacki, Ruth A. Keri, Candece L. Gladson*

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Background: Macroautophagy/autophagy is considered to play key roles in tumor cell evasion of therapy and establishment of metastases in breast cancer. High expression of LC3, a residual autophagy marker, in primary breast tumors has been associated with metastatic disease and poor outcome. FIP200/Atg17, a multi-functional pro-survival molecule required for autophagy, has been implicated in brain metastases in experimental models. However, expression of these proteins has not been examined in brain metastases from patients with breast cancer. Methods: In this retrospective study, specimens from 44 patients with brain metastases of infiltrating ductal carcinoma of the breast (IDC), unpaired samples from 52 patients with primary IDC (primary-BC) and 16 matched-paired samples were analyzed for LC3 puncta, expression of FIP200/Atg17, and p62 staining. Results: LC3-puncta+ tumor cells and FIP200/Atg17 expression were detected in greater than 90% of brain metastases but there were considerable intra- and inter-tumor differences in expression levels. High numbers of LC3-puncta+ tumor cells in brain metastases correlated with a significantly shorter survival time in triple-negative breast cancer. FIP200/Atg17 protein levels were significantly higher in metastases that subsequently recurred following therapy. The percentages of LC3 puncta+ tumor cells and FIP200/Atg17 protein expression levels, but not mRNA levels, were significantly higher in metastases than primary-BC. Meta-analysis of gene expression datasets revealed a significant correlation between higher FIP200(RB1CC1)/Atg17 mRNA levels in primary-BC tumors and shorter disease-free survival. Conclusions: These results support assessments of precision medicine-guided targeting of autophagy in treatment of brain metastases in breast cancer patients.

Original languageEnglish (US)
Pages (from-to)237-248
Number of pages12
JournalJournal of Neuro-Oncology
Volume140
Issue number2
DOIs
StatePublished - Nov 15 2018

Keywords

  • Autophagy
  • Brain metastases of breast cancer
  • FIP200/Atg17
  • LC3
  • Recurrence
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Expression of LC3B and FIP200/Atg17 in brain metastases of breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Hashemi-Sadraei, N., Müller-Greven, G. M., Abdul-Karim, F. W., Ulasov, I., Downs-Kelly, E., Burgett, M. E., Lauko, A., Qadan, M. A., Weil, R. J., Ahluwalia, M. S., Du, L., Prayson, R. A., Chao, S. T., Budd, T. G., Barnholtz-Sloan, J., Nowacki, A. S., Keri, R. A., & Gladson, C. L. (2018). Expression of LC3B and FIP200/Atg17 in brain metastases of breast cancer. Journal of Neuro-Oncology, 140(2), 237-248. https://doi.org/10.1007/s11060-018-2959-5